The epidemiological picture is striking. Across population studies, diabetes is associated with a two- to four-fold increase in both the incidence and recurrence of urinary tract infections. A meta-analysis encompassing 15 studies and 827,948 individuals with type 2 diabetes estimated a prevalence of roughly 11.5 percent, while asymptomatic bacteriuria, the silent presence of bacteria in the bladder without symptoms, has been reported in 23.7 percent of type 2 diabetes patients. More recent studies suggest the burden may be even higher in certain populations, with prevalence reaching up to 39.3 percent and overall risk nearly doubled compared with people without diabetes. Recurrence is a defining feature: reported rates range from approximately 23 to 37 percent, and diabetes has been identified as an independent risk factor for progression from a first episode of cystitis to recurrent disease.

The microbiology is equally revealing. Uropathogenic Escherichia coli remains the dominant cause of uncomplicated infections in diabetic and non-diabetic patients alike, accounting for roughly 60 to 71 percent of isolates across studies. But in diabetes the spectrum broadens considerably: Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterococcus species, Enterobacter species, and, less frequently, Candida albicans all appear more often. Critically, patients with diabetes carry a higher prevalence of antimicrobial-resistant pathogens, including extended-spectrum beta-lactamase (ESBL)-producing strains of E. coli and K. pneumoniae. One comparative study cited in the review found resistance to at least one antimicrobial agent in 92.5 percent of isolates from diabetic patients versus 75.0 percent from non-diabetic controls, with particularly large gaps for amoxicillin (85.0 versus 67.5 percent), amoxicillin/clavulanic acid (57.5 versus 37.5 percent), ciprofloxacin (38.8 versus 20.0 percent), and ceftriaxone (25.0 versus 7.5 percent).

Why does hyperglycemia so profoundly reshape infection risk? The review lays out a layered mechanistic explanation. Chronic high blood glucose spills into the urine as glucosuria once plasma levels exceed the renal reabsorption threshold, creating a nutrient-rich environment that fuels bacterial growth. Simultaneously, hyperglycemia impairs innate and adaptive immune defenses: neutrophils show reduced chemotaxis, phagocytosis, and oxidative burst, while the antimicrobial peptide psoriasin, which normally controls bacterial growth at mucosal surfaces, is downregulated. Diabetic autonomic neuropathy adds a mechanical dimension, causing incomplete bladder emptying and urinary stasis that facilitate bacterial colonization. Hyperglycemia also disrupts the uroepithelial barrier itself, weakening intercellular junctions and altering receptor expression in ways that promote bacterial adhesion and deeper tissue invasion.

The bacterial side of the story is just as dynamic. UPEC initiates infection by adhering to uroepithelial cells through type 1 and P pili, with the FimH adhesin at the tip of type 1 pili driving bacterial internalization and the formation of intracellular bacterial communities that shield the pathogen from both immune attack and antibiotics. P pili, particularly class II variants, are associated with upper urinary tract colonization and heightened renal inflammation under diabetic conditions. UPEC also deploys an arsenal of virulence factors, including hemolysin A, cytotoxic necrotizing factor 1, the curli fiber protein CsgA, the serum resistance protein TraT, and group 2 capsule factors, which together promote tissue damage, biofilm formation, and immune evasion. Experimental work suggests that elevated glucose acts as both a metabolic substrate and a signaling cue, upregulating virulence-associated genes and enhancing biofilm production, which in turn increases tolerance to antibiotics and host defenses.

Perhaps the most clinically consequential insight is the bidirectional feedback loop between infection and glycemia. When a urinary tract infection takes hold, the body’s stress response releases counterregulatory hormones that increase hepatic glucose production and reduce insulin sensitivity, driving blood sugar upward. Inflammatory processes accompanying the infection further aggravate insulin resistance, and persistent low-grade inflammation can intensify this effect, particularly in patients with impaired renal function. The practical implication is that an unexplained rise in blood glucose in a diabetic patient should prompt consideration of an occult urinary infection, and conversely, that treating the infection is inseparable from restoring metabolic control. Hospitalized patients typically require structured glucose monitoring and insulin-centered regimens, with careful adjustment based on glucose trends and clinical status.

The review also tackles a modern therapeutic dilemma: sodium-glucose cotransporter 2 (SGLT2) inhibitors. These widely prescribed drugs deliberately induce glucosuria, sometimes exceeding 60 to 70 grams of urinary glucose per day in patients with preserved renal function, to improve glycemic control and deliver cardiovascular and renal benefits. The concern is obvious: does pharmacologically sweetened urine cultivate infection? The evidence is nuanced. Randomized controlled trials and meta-analyses generally show no significant increase in urinary tract infection risk with SGLT2 inhibitors, while observational studies suggest only a modest elevation that appears driven more by impaired kidney function and prior genitourinary infections than by glycemic status alone. In contrast, genital infection risk is consistently and markedly increased, more than threefold, particularly in women and those with a history of such infections, though these episodes are typically mild and respond well to standard treatment. The authors note that experimental studies supporting a role for urinary glucose in bacterial growth and UPEC virulence do not fully align with clinical observations from patients on SGLT2 inhibitors, leaving the contribution of glucosuria itself incompletely understood.

Clinical presentation adds another layer of complexity. While diabetic patients may experience classic symptoms such as dysuria, urinary frequency, and lower abdominal pain, atypical or muted symptoms are common and can delay diagnosis. When infection does take hold, it is more likely to escalate: the review catalogs a higher incidence of acute pyelonephritis, renal abscesses, emphysematous cystitis and pyelonephritis, and urosepsis in diabetic populations. These severe outcomes are attributed primarily to hyperglycemia-induced immune impairment, glucosuria, urinary stasis from neuropathy, and chronic inflammation rather than to diabetes type itself. Notably, patients over 45 years of age appear particularly susceptible, and type 2 diabetes is associated with more frequent infections than type 1, most likely because of higher rates of obesity, insulin resistance, poorer glycemic control, and chronic complications rather than the diabetes type per se.

Looking forward, the authors identify several promising therapeutic frontiers. Because hyperglycemia both impairs host defenses and enhances bacterial virulence, optimized glycemic control remains foundational, potentially reducing glucosuria-associated bacterial growth and partially restoring antimicrobial peptide expression. Targeting biofilm formation, which drives persistence and recurrence especially under hyperglycemic conditions, offers another avenue, as does modulating host immune responses, including interference with the AGE-RAGE-NF-kappa-B inflammatory axis that sustains tissue damage without effective pathogen clearance. Anti-virulence therapies that disarm bacterial toxins, adhesion factors, and immune evasion mechanisms could reduce pathogenicity without imposing the selective pressure that fuels antibiotic resistance. For multidrug-resistant UPEC strains carrying blaCTX-M, blaTEM, and blaSHV beta-lactamase genes, the review highlights bacteriophage therapy, microbiome-based interventions, and probiotic strategies as promising adjuncts, and points to genomics, transcriptomics, and metabolomics as tools for uncovering novel targets in hyperglycemia-driven immune dysfunction.

The review is candid about the limits of current knowledge. Most mechanistic evidence derives from in vitro experiments and animal models, while human studies remain predominantly observational, making it difficult to isolate the independent effect of hyperglycemia from coexisting diabetic complications, immune dysfunction, and structural abnormalities of the urinary tract. Heterogeneity in study populations, diagnostic criteria, and definitions of recurrent infection further complicates cross-study comparison. Yet the clinical message is unambiguous: urinary tract infections in diabetes demand integrated management that treats the infection promptly with culture-guided antimicrobials while simultaneously stabilizing blood glucose, with particular vigilance in patients with advanced kidney disease who may swing between hyperglycemia and hypoglycemia. As antimicrobial resistance continues to climb, understanding the molecular dialogue between a sugar-laden urinary tract and an adaptable pathogen may prove essential to protecting one of medicine’s most vulnerable populations.

Subject of Research: The bidirectional relationship between diabetes mellitus and urinary tract infections, covering epidemiology, UPEC pathogenesis, glucosuria, immune dysfunction, and management strategies

Article Title: Urinary tract infections in diabetes: clinical significance and management approaches

Article References: Zalewska-Piątek, B., Nagórka, M., & Piątek, R. (2026). Urinary tract infections in diabetes: clinical significance and management approaches. Acta Biochimica Polonica, 73, Article 17198. https://doi.org/10.3389/abp.2026.17198

Image Credits: AI Generated

DOI: 10.3389/abp.2026.17198

Keywords: diabetes mellitus, urinary tract infections, uropathogenic Escherichia coli, hyperglycemia, glucosuria, SGLT2 inhibitors, antimicrobial resistance, biofilms, immune dysfunction, glycemic control, ESBL, bacteriophage therapy

The research, led by Muhammet Fatih Şahin of the Department of Internal Medicine at Kestel State Hospital in Bursa and colleagues at collaborating institutions, was published in BMC Endocrine Disorders as an open-access research article. The team set out to answer a deceptively simple question: among people with type 2 diabetes who undergo clinically indicated dual-energy X-ray absorptiometry, do those taking SGLT2 inhibitors show worse bone health than those who do not? To address it, the investigators assembled a primary analytical cohort of 56 patients with type 2 diabetes who were referred for DEXA scanning between June 2025 and February 2026. Of these, 31 patients were not using SGLT2 inhibitors and 25 were. A separate group of 44 participants without diabetes was recruited purely for secondary, descriptive comparisons, providing a reference point for how bone health parameters distribute in people free of the metabolic disease.

The choice of measurement technique matters enormously in this field, and the study leaned on the gold standard. Dual-energy X-ray absorptiometry, or DEXA, works by firing two X-ray beams of different energies through the body and measuring how much each is attenuated by bone tissue. Because calcium in bone absorbs X-rays far more efficiently than soft tissue, the differential attenuation allows clinicians to calculate bone mineral density with remarkable precision at clinically relevant sites. The researchers focused on the lumbar spine and the femoral neck, the narrow segment of the thigh bone just below the hip joint where fractures are both common and devastating. Each participant received a T-score at these sites, a number that expresses bone density as a comparison against the average peak bone mass of a healthy young adult. A T-score of minus 2.5 or lower at either site defines osteoporosis, while values between minus 1.0 and minus 2.5 fall into the intermediate territory of osteopenia.

The headline result was a statistical null. Osteoporosis, defined as a T-score of minus 2.5 or below at the lumbar spine or femoral neck, was present in 32.3 percent of the patients with type 2 diabetes who were not taking SGLT2 inhibitors and in 36.0 percent of those who were, a difference that was statistically indistinguishable with a p-value of 0.769. When the investigators moved beyond raw prevalence and applied logistic regression, adjusting for age, sex, and body mass index, the odds ratio for osteoporosis associated with SGLT2 inhibitor exposure came out at 1.169 with a 95 percent confidence interval stretching from 0.328 to 4.170, and a p-value of 0.810. An odds ratio of 1.0 would indicate no effect at all; the observed value of 1.169 hints at a modestly elevated risk, but the confidence interval is so wide that it comfortably spans everything from a strong protective effect to a more than fourfold increase in risk. In plain terms, the data cannot tell readers which direction, if any, the true effect points.

The null findings extended across every secondary outcome the team examined. There was no significant association between SGLT2 inhibitor use and the worst T-score recorded for each patient, nor with the site-specific T-scores at the lumbar spine or femoral neck. Actual bone mineral density measurements at both anatomical sites likewise showed no meaningful differences between users and non-users of the drug class. Even when patients were sorted into broader bone mineral density risk categories, normal, osteopenic, or osteoporotic, based on the worse of their two T-scores, the distribution did not differ significantly between the groups. A supplementary analysis incorporating the non-diabetic comparison group, evaluated with a Fisher–Freeman–Halton exact test, found no significant difference in bone mineral density category distribution across all three groups, with a p-value of 0.809. For a drug class that has been shadowed by skeletal concerns, the consistency of the null results across so many related endpoints is itself informative.

Why, then, did the skeletal question arise in the first place? The biological plausibility of harm has never been trivial. SGLT2 inhibitors induce a mild state of glucosuria, and the resulting caloric and fluid shifts alter phosphate handling, insulin secretion, and parathyroid hormone dynamics, all of which participate in the delicate regulation of bone remodeling. Some earlier observational studies and post-marketing analyses raised flags about fracture risk, particularly with canagliflozin, prompting regulators to add warnings to drug labels. At the same time, type 2 diabetes itself complicates the picture in a way that standard DEXA measurements can underappreciate. People with diabetes can sustain fragility fractures at bone densities that would be considered safe in the general population, a phenomenon thought to reflect impaired bone quality, altered collagen cross-linking, and the added danger of hypoglycemia-related falls. Any study of diabetes drugs and bone health therefore has to contend with a disease process that already distorts the relationship between measured density and actual fracture risk.

The authors of the new study are careful, and appropriately so, about what their results can and cannot support. In their conclusion they state that no statistically significant association was detected between SGLT2 inhibitor use and DEXA-derived bone health outcomes in patients with type 2 diabetes, but they immediately qualify this by noting that the limited sample size and the wide confidence intervals preclude excluding clinically meaningful associations. They call for larger prospective studies to settle the question. This is the honest language of exploratory research: a study of 56 patients simply lacks the statistical power to detect anything but a very large effect. With confidence intervals as broad as those reported here, a true doubling of osteoporosis risk could hide within the data undetected. Readers and clinicians should therefore interpret the findings as absence of evidence rather than evidence of absence, a distinction that matters when treatment decisions hang in the balance.

The study’s design also carries limitations worth understanding. As an observational, cross-sectional analysis conducted at a single hospital department, it captured patients at one moment in time rather than following them as bone density evolved. Patients were not randomized to receive SGLT2 inhibitors, so the possibility of confounding by indication, where the reasons a clinician chose a particular drug correlate with other health factors, cannot be fully excluded even with adjustment for age, sex, and body mass index. The duration of SGLT2 inhibitor exposure among users was not a central variable in the reported analysis, yet skeletal effects of any drug typically accumulate over years. The inclusion of a non-diabetic comparison group adds descriptive context, but the core inference rests on the 56 patients with diabetes divided into two modest groups. Ethics approval was granted by the Institutional Ethics Committee of Bursa Yüksek İhtisas Training and Research Hospital, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki, underscoring that the study met standard procedural safeguards even within its constrained scope.

For the millions of people taking SGLT2 inhibitors worldwide, the practical message is one of cautious reassurance rather than definitive clearance. The study found osteoporosis to be strikingly common in this population regardless of medication, affecting roughly a third of patients in both groups, which reinforces the importance of bone health screening for people with type 2 diabetes independent of their glucose-lowering regimen. Clinicians already weigh fracture risk when selecting diabetes therapies, and these findings do not demand a change in that calculus. What the research does provide is a template for the kind of work that must come next: large, prospective cohorts with longitudinal DEXA monitoring, careful documentation of drug duration and dose, and ideally fracture outcomes rather than surrogate density measures alone. Until such studies arrive, the skeleton’s verdict on SGLT2 inhibitors remains open, but the scales have tilted slightly, and measurably, toward the reassuring side.

Subject of Research: The association between SGLT2 inhibitor use and DEXA-derived bone health parameters in patients with type 2 diabetes mellitus

Article Title: SGLT2 inhibitor use and DEXA-derived bone health in type 2 diabetes mellitus

Article References: Şahin, M. F., Şahin, A., Dinar, A. B. K., Avul, S., İzeet, S. N., & Erol, A. (2026). SGLT2 inhibitor use and DEXA-derived bone health in type 2 diabetes mellitus. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02633-z

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02633-z

Keywords: SGLT2 inhibitors, type 2 diabetes, osteoporosis, bone mineral density, DEXA, T-score, BMC Endocrine Disorders, observational study, endocrinology, fragility fractures, glucosuria, bone health